T-Therapeutics Ltd
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing their proprietary OpTiMus® platform, they create unique, antigen-specific human TCRs aimed at transforming cancer treatment. The company combines expertise in mouse genome engineering, biopharmaceutical development, and machine learning, fostering a culture of innovation and collaboration. With a strong commitment to scientific excellence, T-Therapeutics is positioned to reshape the clinical landscape for patients.
T-Therapeutics Ltd
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing their proprietary OpTiMus® platform, they create unique, antigen-specific human TCRs aimed at transforming cancer treatment. The company combines expertise in mouse genome engineering, biopharmaceutical development, and machine learning, fostering a culture of innovation and collaboration. With a strong commitment to scientific excellence, T-Therapeutics is positioned to reshape the clinical landscape for patients.
TL;DR
Headquarters: Cambridge, UK (Granta Park)
Technology: OpTiMus® fully humanized TCR mouse platform
Focus: TCR-based therapeutics for cancer and autoimmune diseases
Founded: 2022
Notable investors: Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, Business Growth Fund
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Cancer and autoimmune disease therapeutics development using T cell receptor-based approaches.
Founded
2022
Industry
Biotechnology
Funding Track Record
£48,000,000
Company announced a £48M Series A on 15 November 2023.
32,000,000
Dealroom lists a Series A of $32.0M in Nov 2025 and company communications indicate additional investors (Tencent, Business Growth Fund) increasing round totals.
Investor Signal
“Backed by multiple blue-chip life sciences investors including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital and Sanofi Ventures; later participation noted from Tencent and Business Growth Fund.”